Takeda Pharmaceutical Company Limited SEC filings document its reporting as a foreign private issuer and ADR-listed pharmaceutical company that furnishes Form 6-K current reports and files annual reports on Form 20-F. The filings include English-language earnings reports, financial appendices, press releases and governance notices.
Takeda’s regulatory disclosures cover IFRS consolidated results, outlook commentary, ADR and foreign-issuer reporting status, board and representative-director matters, corporate transformation initiatives, and clinical or regulatory updates for programs such as zasocitinib, rusfertide and oveporexton. The filings also document pipeline-related financial-impact statements, shareholder meeting materials and formal exhibits furnished to the SEC.
Takeda Pharmaceutical Co Ltd's President, IBU, Giles Richard Platford, sold 55,617 American Depositary Shares on November 4, 2026, at $20.90 per share. His reported direct holdings after the sale were 270,253 American Depositary Shares, including 10,032 ADS received upon vesting of dividend equivalent units that were not included in his previously filed Form 4. No Rule 10b5-1 plan is reported.
Takeda Pharmaceutical Co Ltd President, OBU, Teresa Marie Bitetti sold 46,609 American Depositary Shares on November 2, 2026, at $20.89 per share. Her reported direct holdings after the sale were 214,501 American Depositary Shares, including 9,100 ADS received upon vesting of dividend equivalent units that were not included in her previously filed Form 4. No Rule 10b5-1 plan is reported for the transaction.
Takeda Pharmaceutical Co Ltd (TAK) is named as issuer in a notice reporting that Giles Richard Platford, President, International Business Unit, proposes to sell 55,617 American Depositary Shares (ADSs), with an aggregate market value of $1,121,794.89. Interactive Brokers LLC is listed as broker, NYSE as the exchange, and November 1, 2026, as the approximate sale date. The notice also lists 31,083 ADSs sold on August 10, 2026, for $531,519.30. Its remarks state that the sale during the past three months was conducted to satisfy tax obligations connected with share vesting effective July 13, 2026.
Takeda Pharmaceutical Company Limited is identified as the issuer in Teresa Bitetti’s notice proposing a sale of 46,609 American Depositary Shares (ADSs), with an aggregate market value of $940,103.53 and an approximate sale date of November 1, 2026. Bitetti, President, Global Oncology Business Unit, previously sold 50,012 ADSs on August 10, 2026, for $855,205.20. The notice says that sale was conducted to satisfy tax obligations in connection with share vesting effective July 13, 2026.
Takeda Pharmaceutical Company Limited reported revenue of JPY 2,407.0 billion for the six months ended September 30, 2026, up 8.4% on an actual exchange rate (AER) basis but down 1.0% at constant exchange rates (CER); the reported increase was primarily attributable to depreciation of the yen. Operating profit rose 60.4% AER to JPY 406.7 billion, and net profit attributable to owners rose 171.8% AER to JPY 305.6 billion.
Core operating profit was JPY 710.6 billion, up 11.2% AER and 0.7% CER, while core net profit attributable to owners was JPY 489.6 billion, up 11.6% AER and down 0.2% CER. Net cash from operating activities declined JPY 161.8 billion year over year to JPY 431.9 billion, and cash and cash equivalents were JPY 418.5 billion as of September 30, 2026. Takeda also reported U.S. approval of ORZEYFUL for adults with narcolepsy type 1 and FDA approval of MIMRYLO for adults with polycythemia vera.
Takeda Pharmaceutical Company Limited (TAK) reported first-half FY2026 revenue of JPY 2,407.0 billion, up 8.4% at actual exchange rates (AER) but down 1.0% at constant exchange rates (CER), as yen depreciation primarily drove the reported increase. Operating profit was JPY 406.7 billion, up 60.4% AER and 45.0% CER; net profit attributable to owners was JPY 305.6 billion, up 171.8% AER. Profit results also reflected lower product-asset amortization and impairment losses and deferred tax benefits.
Takeda revised its FY2026 reported forecasts to revenue of JPY 4,700.0 billion, operating profit of JPY 453.0 billion and net profit attributable to owners of JPY 209.0 billion. CER-based core guidance still projects declines: low-single digit for Core Revenue, mid-single digit for Core Operating Profit and low-teens for Core EPS. The board approved a JPY 102 per-share interim dividend, payable December 1, 2026; the annual dividend projection is JPY 204 per share. First-half net cash from operating activities was JPY 431.9 billion, down 27.2% year over year; cash and cash equivalents were JPY 418.5 billion as of September 30, 2026.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported that Chief Transformation Officer Lauren Rusckowski Duprey sold 34,535 American Depositary Shares on September 14, 2026 in an open-market or private transaction at $18.54 per share. After this sale, she directly holds 191,522 American Depositary Shares, and no Rule 10b5-1 plan is reported.
Takeda Pharmaceutical Co. (TAK) reports that the U.S. FDA has accepted, under Priority Review, its New Drug Application for zasocitinib (TAK-279), an investigational oral TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis. The Prescription Drug User Fee Act target action date is in the first quarter of 2027.
The application is backed by global Phase 3 LATITUDE PsO 3001 and 3002 studies, which met all primary and ranked secondary endpoints and showed about 70% of patients achieved clear or almost clear skin at week 16, with a safety profile consistent with earlier studies. A Phase 3 open-label study (LATITUDE PsO 3003) in roughly 2,100 participants supports long‑term safety and efficacy, and a marketing authorization application has also been accepted by the EMA. Takeda states this NDA filing has no significant impact on its full-year consolidated financial forecast for the fiscal year ending March 31, 2027.
Takeda Pharmaceutical Company Limited’s Chief Transformation Officer, Lauren Rusckowski Duprey, gave notice of a proposed sale of 34,535 American Depositary Shares (ADSs), with an aggregate market value of $634,407.95 and an approximate sale date of September 10, 2026. The ADSs were acquired through restricted stock unit awards that vested on July 30, 2024. A separate sale of 47,586 ADSs occurred on July 13, 2026, for gross proceeds of $813,720.60; it was conducted to satisfy tax obligations connected with share vesting effective that date.
TAKEDA PHARMACEUTICAL CO LTD (TAK) reported that Andrew Stewart Plump, its President of R&D and a director, sold 116,191 American Depositary Shares on September 2, 2026 at $18.49 per share through a trust. The trust held 145,465 ADS after the sale, and he also reported 766,569 ADS held directly. The sale was made under a Rule 10b5-1 trading plan adopted on May 15, 2026.